In addition to its ability to accelerate remyelination following acute cuprizone administration (Zendedel et al., 2016; Hartley et al., 2019), there is emerging evidence from our group suggesting that MCT8 is also downregulated in neuroinflammatory conditions seen in MS. This evidence concerns the gene SLC16A2 and myeloid sarcoma.